Free Trial

Plus Therapeutics (PSTV) Stock Forecast & Price Target

Plus Therapeutics logo
$0.30 -0.01 (-3.65%)
Closing price 07/3/2025 03:59 PM Eastern
Extended Trading
$0.30 +0.00 (+0.34%)
As of 07/3/2025 04:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Plus Therapeutics - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Sell
0
Hold
2
Buy
2

Based on 4 Wall Street analysts who have issued ratings for Plus Therapeutics in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 4 analysts, 2 have given a hold rating, and 2 have given a buy rating for PSTV.

Consensus Price Target

$10.83
3,559.91% Upside
According to the 4 analysts' twelve-month price targets for Plus Therapeutics, the average price target is $10.83. The highest price target for PSTV is $20.50, while the lowest price target for PSTV is $3.00. The average price target represents a forecasted upside of 3,559.91% from the current price of $0.30.
Get the Latest News and Ratings for PSTV and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Plus Therapeutics and its competitors.

Sign Up

PSTV Analyst Ratings Over Time

TypeCurrent Forecast
7/5/24 to 7/5/25
1 Month Ago
6/5/24 to 6/5/25
3 Months Ago
4/6/24 to 4/6/25
1 Year Ago
7/6/23 to 7/5/24
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
2 Buy rating(s)
2 Buy rating(s)
3 Buy rating(s)
1 Buy rating(s)
Hold
2 Hold rating(s)
2 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$10.83$11.67$11.17$8.00
Forecasted Upside3,559.91% Upside3,557.26% Upside1,315.11% Upside416.13% Upside
Consensus Rating
Moderate Buy
Moderate Buy
Buy
Buy

PSTV Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

PSTV Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Plus Therapeutics Stock vs. The Competition

TypePlus TherapeuticsMedical CompaniesS&P 500
Consensus Rating Score
2.50
2.80
2.53
Consensus RatingModerate BuyModerate BuyModerate Buy
Predicted Upside3,559.91% Upside8,541.72% Upside9.83% Upside
News Sentiment Rating
Neutral News

See Recent PSTV News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
6/27/2025HC Wainwright
1 of 5 stars
Sean Lee
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower TargetBuy ➝ Buy$5.50 ➝ $3.00+718.31%
6/25/2025D. Boral Capital
0 of 5 stars
Jason Kolbert
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingHold ➝ Hold$9.00+4,712.58%
6/5/2025Ascendiant Capital Markets
1 of 5 stars
Edward Woo
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetBuy ➝ Buy$20.00 ➝ $20.50+5,712.14%
5/5/2025D Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
J. Kolbert
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Saturday at 09:17 AM ET.


PSTV Forecast - Frequently Asked Questions

According to the research reports of 4 Wall Street equities research analysts, the average twelve-month stock price forecast for Plus Therapeutics is $10.83, with a high forecast of $20.50 and a low forecast of $3.00.

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Plus Therapeutics in the last twelve months. There are currently 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" PSTV shares.

According to analysts, Plus Therapeutics's stock has a predicted upside of 3,559.91% based on their 12-month stock forecasts.

Over the previous 90 days, Plus Therapeutics's stock had 1 downgrade by analysts.

Plus Therapeutics has been rated by research analysts at Ascendiant Capital Markets, D Boral Capital, D. Boral Capital, and HC Wainwright in the past 90 days.

Analysts like Plus Therapeutics less than other "medical" companies. The consensus rating score for Plus Therapeutics is 2.50 while the average consensus rating score for "medical" companies is 2.80. Learn more on how PSTV compares to other companies.


This page (NASDAQ:PSTV) was last updated on 7/5/2025 by MarketBeat.com Staff
From Our Partners